Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31076279 | 0.86 | FFAR4 (0.41) | MKNK1MKNK2P2RX7CYP2C9 | |
| SCHEMBL30715019 | 0.83 | NAPRT (0.42) | MKNK1MKNK2P2RX7SLC9A1NPC1 | |
| SCHEMBL30715028 | 0.81 | SLC9A1 (0.44) | P2RX7SLC9A1NPC1MAPTRAB9A | |
| SCHEMBL31355231 | 0.75 | MAP4K1 (0.33) | SLC9A1IRAK4FAAHALDH1A1CYP1A2 | |
| SCHEMBL31355234 | 0.74 | OPRM1 (0.41) | P2RX7SLC9A1NPC1MAPTRAB9A | |
| SCHEMBL30243669 | 0.72 | GPR88 (0.45) | NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL21439582 | 0.71 | SLC9A1 (0.43) | SLC9A1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4138471 | 0.70 | KDM1A (0.55) | SLC9A1ALDH1A1 | |
| SCHEMBL15541759 | 0.70 | KDM1A (0.56) | SLC9A1MAPTALDH1A1 | |
| SCHEMBL15541112 | 0.70 | KDM1A (0.56) | SLC9A1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | claimed |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | claimed |
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | MKNK1 2331/4885MKNK2 2295/4885P2RX7 4090/4885 |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | MKNK1 2331/4885MKNK2 2295/4885P2RX7 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.